Literature DB >> 23975055

The influence of desmocollin 1-3 expression on prognosis after curative resection of colorectal liver metastases.

Silke Schüle1, Claudia Neuhäuser, Falk Rauchfuß, Thomas Knösel, Utz Settmacher, Annelore Altendorf-Hofmann.   

Abstract

PURPOSE: Prognosis after curative resection of colorectal liver metastases is hard to determine based on clinical parameters; biomarkers are therefore needed. The purpose of this study was to determine the value of desmocollins (DSC) as potential biomarkers. Desmocollins are responsible for cell-cell adhesion in epithelial tissue; their loss may lead to reduced cellular adhesion and facilitate cellular migration, enabling tumor cells to form distant metastases. We analyzed DSC expression in colorectal liver metastases with respect to the risk of recurrence following liver resection.
METHODS: Tissue microarrays from 257 consecutive patients who underwent R0-resection of colorectal liver metastases were constructed.
RESULTS: Low expression of DSC 1, 2, and 3 was observed in 55, 54, and 79 % of liver metastases. There was no correlation between site or stage of the primary tumor, presence of extrahepatic tumor, grading, size or number of metastases, and desmocollin expression. Primary tumor stage I or II (p = 0.005) and no or few lymph node metastases (p < 0.001) were associated with a significantly better disease-free survival on univariate analysis. These parameters reached only marginal significance on multivariate analysis (p = 0.059 and p = 0.052, respectively), as did desmocollin 3 expression (p = 0.050). In the subgroup of patients with stages III-IV primary tumors, however, multivariate analysis showed a significant correlation between DSC 3 expression and disease-free survival after liver resection (p = 0.009).
CONCLUSIONS: Reduced expression of DSC3 correlated with an increased risk of developing tumor recurrence after resection of liver metastases. These findings may be helpful in selecting high-risk patients who might benefit from multimodal therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23975055     DOI: 10.1007/s00384-013-1765-y

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  21 in total

1.  Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer.

Authors:  Thomas Knösel; Anna Emde; Karsten Schlüns; Yuan Chen; Karsten Jürchott; Matthias Krause; Manfred Dietel; Iver Petersen
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

2.  Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma.

Authors:  Zaur Hamidov; Annelore Altendorf-Hofmann; Yuan Chen; Utz Settmacher; Iver Petersen; Thomas Knösel
Journal:  J Clin Pathol       Date:  2011-07-01       Impact factor: 3.411

3.  Search for transmembrane protein in gastric cancer by the Escherichia coli ampicillin secretion trap: expression of DSC2 in gastric cancer with intestinal phenotype.

Authors:  Katsuhiro Anami; Naohide Oue; Tsuyoshi Noguchi; Naoya Sakamoto; Kazuhiro Sentani; Tetsutaro Hayashi; Takao Hinoi; Masazumi Okajima; Jonathan M Graff; Wataru Yasui
Journal:  J Pathol       Date:  2010-07       Impact factor: 7.996

4.  Cell adhesion and communication proteins are differentially expressed in melanoma progression model.

Authors:  Gisele Gargantini Rezze; José Humberto Tavares Guerreiro Fregnani; João Duprat; Gilles Landman
Journal:  Hum Pathol       Date:  2010-12-28       Impact factor: 3.466

5.  Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system.

Authors:  S Iwatsuki; I Dvorchik; J R Madariaga; J W Marsh; F Dodson; A C Bonham; D A Geller; T J Gayowski; J J Fung; T E Starzl
Journal:  J Am Coll Surg       Date:  1999-09       Impact factor: 6.113

6.  Hepatic resection for colorectal metastases: value for risk scoring systems?

Authors:  Shaheen Zakaria; John H Donohue; Florencia G Que; Michael B Farnell; Cathy D Schleck; Duane M Ilstrup; David M Nagorney
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

Review 7.  Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases.

Authors:  R P Jones; R Jackson; D F J Dunne; H Z Malik; S W Fenwick; G J Poston; P Ghaneh
Journal:  Br J Surg       Date:  2012-01-19       Impact factor: 6.939

8.  DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer.

Authors:  T Cui; Y Chen; L Yang; T Knösel; K Zöller; O Huber; I Petersen
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

9.  Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients.

Authors:  M P Myklebust; Ø Fluge; H Immervoll; A Skarstein; L Balteskard; O Bruland; O Dahl
Journal:  Br J Cancer       Date:  2012-02-14       Impact factor: 7.640

10.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

View more
  1 in total

1.  Lower DSC1 expression is related to the poor differentiation and prognosis of head and neck squamous cell carcinoma (HNSCC).

Authors:  Yating Wang; Chen Chen; Xiaofei Wang; Fengtong Jin; Yan Liu; Huiqiao Liu; Ting Li; Jiangtao Fu
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-06       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.